Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages 1102-1106

  Casale, Maddalena ^a   Citarella, Serena ^a   Filosa, Aldo ^b   De Michele, Elisa ^c   Palmieri, Francesco ^d   Ragozzino, Alfonso ^d   Amendola, Giovanni ^e   Pugliese, Umberto ^a   Tartaglione, Immacolata ^a   Della Rocca, Filomena ^a   Cinque, Patrizia ^b   Nobili, Bruno ^a   Perrotta, Silverio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

^d Ospedale S Maria delle Grazie   (Italy)

^e Ospedale Umberto I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEFERASIROX; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIOTHYRONINE; PARATHYROID HORMONE; THYROTROPIN; THYROXINE; VITAMIN D; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CHELATION THERAPY; CHILD; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED PUBERTY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; GROWTH RETARDATION; HEMOGLOBIN BLOOD LEVEL; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN TREATMENT; IRON CHELATION; LIOTHYRONINE BLOOD LEVEL; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTICENTER STUDY; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREGNANCY; PRIORITY JOURNAL; SUBCLINICAL HYPOTHYROIDISM; THALASSEMIA MAJOR; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRANSFUSION; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; BETA-THALASSEMIA; BONE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; IRON OVERLOAD; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PUBERTY, DELAYED; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; BONE AND BONES; BONE DENSITY; CALCIUM; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; DIPHOSPHONATES; FEMALE; HUMANS; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; OSTEOPOROSIS; PUBERTY, DELAYED; RETROSPECTIVE STUDIES; TRIAZOLES; VITAMIN D;

EID: 84922393499     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23844     Document Type: Article

References (26)

1. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood 2012;120(18):3657-3669.
2. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-3488.
3. Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program 2011:2011:443-450.
4. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica 2012;97(6):842-848.
5. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores. Blood 2010;116(4):537-543.
6. Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011;141(4):1202-1211.
7. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009;114:4021-4026.
8. Belhoul KM, Bakir ML, Saned MS, et al. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol 2012;91(7):1107-1114.
9. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2012;87(2):167-171.
10. Noetzli LJ, Mittelman SD, Watanabe RM, et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012;87(2):155-160.
11. Westwood M, Anderson LJ, Firmin DN, et al. A single breathhold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003;18:33-39.
12. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005;106(4):1460-1465.
13. Cappellini MD, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of Thalassaemia, 2nd Revised Edition. Nicosia, Cyprus: Thalassemia International Federation; 2008.
14. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
15. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of β-thalassemia major in North America. Blood 2004;104:34-39.
16. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol. 2009;146:546-556.
17. De Sanctis V, Eleftheriou A, Malaventura C. Thalassemia International Federation Study Group on growth and endocrine complications in thalassemia. Prevalence of endocrine complications and short stature in patients with thalassemia major: A major multicenter study by the Thalassemia International Federation (TIF). Ped Endocrin Rev 2004; 2(2):249-255.
18. Gamberini MR, Fortini M, De Sanctis V, et al. Diabetes mellitus and impaired glucose tolerance in thalassemia major: Incidence, prevalence, risk factors and survival in patients followed in the Ferrara center. Ped Endocrin Rev 2004;2(2):285-291.
19. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. New Eng J Med 1988;318:809-814.
20. Jensen CE, Tuck SM, Agnew JE, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998;103:911-915.
21. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann NY Acad Sci 1998;850:344-348.
22. Carmina E, Di Fede G, Napoli N, et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 2004;74:68-71.
23. Lasco A, Morabito N, Gaudio A, et al. Effects of hormonal replacement therapy on bone metabolism in young adults with beta- thalassemia major. Osteoporos Int 2001;12:570-575.
24. Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010;148:466-475.
25. Origa R, Piga A, Quarta G, et al. Pregnancy and β-thalassemia: An Italian multicenter experience. Haematologica 2010;95:376-381.
26. Rossi F, Perrotta S, Bellini G, et al. Iron overload causes osteoporosis in Thalassemia Major patients through interaction with TRPV1 channels. Haematologica 2014. doi:10.3324/haematol.2014.104463.